Fusion protein for resisting formation of thrombus targetedly and preparation method and application thereof

Abstract

The invention discloses a fusion protein for resisting formation of thrombus targetedly, which comprises the following parts: (a) protein domains of nematode anticoagulant peptide 5, of which the amino acid sequence has at least 80 percent of similarity with a sequence shown as SEQ ID No.1; (b)protein domains of Hirulog, of which the amino acid sequence has at least 80 percent of similarity with a sequence shown as SEQ ID No.2; (c) protein domains of RGD peptide, consisting of 3 to 10 amino acids and containing an Arg-Gly-Asp sequence; and (d) human coagulation factor X a recognition sites, of which the amino acid sequence is shown as SEQ ID No.3. The invention also discloses a gene encoding the fusion protein, a recombined expression vector containing the gene, a transformant containing the recombined expression vector, and a method for preparing the fusion protein. The prepared fusion protein can inhibit formation and development of thrombus from a plurality of approaches and take effect on thrombus positions targetedly, and is suitable for preventing and treating thrombotic disorders.

Description

technical field [0001] The present invention relates to a fusion protein, in particular to a targeted anti-thrombosis fusion protein, and to a preparation method and application of the fusion protein. Background technique [0002] Under physiological conditions, the hemostatic and coagulation system in the human body is in a state of dynamic balance with the anticoagulant and fibrinolytic system, which is the key to maintaining blood circulation in the body and preventing blood loss. Any abnormality in the functioning of one of these systems can lead to a bleeding disorder or a thrombotic disorder. Thrombotic diseases include venous thrombosis and arterial thrombotic diseases, such as deep venous thrombosis, acute myocardial infarction, unstable angina, acute or chronic intravascular coagulation, thrombocytopenia caused by heparin, reembolization after thrombolysis, etc., serious harm Human life and health have become the main cause of human death and disability, as well as...

AI Technical Summary

Problems solved by technology

Its effect is obviously better than that of heparin, and there is no heparin-induced thrombocytopenia, but its biological half-life is short, its bleeding side effects are strong, and its function is single. sex

Images